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Abstract
Purpose To provide an overview of clinical data supporting the use of cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibi-
tors in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), 
metastatic breast cancer (mBC), from the perspective of the practicing oncologist community.
Methods A recent roundtable discussion was convened by The Breast Cancer Therapy Expert Group (BCTEG) to review 
existing data on this topic and its impact on their current practice.
Results Level 1 evidence now supports use of a CDK 4/6 inhibitor in combination with endocrine therapy for patients with 
HR+, HER2−, mBC. Currently, there are no biomarkers that reliably deine patients who will, or will not, beneit from the 
addition of a CDK 4/6 inhibitor to their endocrine therapy. Additional research is needed to identify the optimal sequencing 
of CDK 4/6 inhibitors in relation to other therapies as well as the optimal duration of therapy; at present, evidence suggests 
that use in the upfront setting is better than waiting for a later line of therapy, or adding after endocrine therapy has started.
Conclusions Thus far, three CDK 4/6 inhibitors—palbociclib, ribociclib, and more recently, abemaciclib—have been 
approved for use in the setting of HR+, HER2−, mBC.  The degrees to which these agents difer in terms of CDK4/6 
ainity, side-efect proiles, dosing, degree of central nervous system (CNS) penetration, optimal use in combination with 
antiestrogen therapy, and across other subsets of breast cancer, remain an active area of investigation.
Keywords Breast cancer · Hormone receptor positive · CDK · Metastatic breast cancer · BCTEG · Cyclin-dependent 
kinase · Endocrine therapy
About the Breast Cancer Therapy Expert 
Group (BCTEG)
The BCTEG is a group of expert physicians and clinical 
researchers who have dedicated their careers to the treatment 
of patients with breast cancer. The purpose of the group is to 
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meet periodically to discuss important developments related 
to breast cancer management, with a particular emphasis on 
new indings and/or areas where guidance from established 
bodies, such as the National Comprehensive Cancer Net-
work (NCCN) and the American Society for Clinical Oncol-
ogy (ASCO), may be unresolved, or less well established. 
The goal is to elicit the group’s opinions on a given topic 
as it relates to their own clinical practices, and more impor-
tantly, how this might impact those practicing in the commu-
nity setting, where breast cancer is only one of many tumor 
types encountered. Importantly, this article is not intended 
to replace any existing guidance, or to be construed as an 
exhaustive review of the topic in question. Rather, its main 
aim is to present a concise synopsis of the relevant data in 
this area, and summarize the opinion of the expert group, as 
gleaned from the meeting discussion.
Meeting objectives and role of funding 
sources
In a previous meeting, the group addressed several key issues 
related to endocrine therapy for hormone receptor-positive 
(HR+) early breast cancer (EBC) [1]. A second BCTEG 
meeting was convened in late August 2017 with the goal 
of conducting an informal roundtable discussion on the use 
of cyclin-dependent kinase (CDK) 4/6 inhibitors for HR+ 
metastatic breast cancer (mBC). An unrestricted educational 
grant for this activity was provided by Eli Lilly and Com-
pany, Pizer Inc., and Novartis Pharmaceuticals Corporation, 
with additional support from Total Health Conferencing, a 
medical education company. The faculty were compensated 
for their participation, and topics of discussion were selected 
by the faculty and by Total Health Conferencing. It is recog-
nized that many of the panelists may have relationships with 
corporate entities, both related and unrelated to the topic in 
question; content of the discussions, and any expert opinions 
presented herein, was intended to be based on the panelists’ 
own expert clinical experience and insight, and is understood 
not to be inluenced by any corporate relationship or interest.
Introduction
Dysregulation of the cell cycle is recognized as a salient 
feature of cancer cells [2–4]. The cyclin-dependent kinases 
(CDKs) 4 and 6 play an important regulatory role in the ini-
tiation of mitosis in the mammalian cell cycle [2–4]. Under 
normal conditions, progression through the cell cycle is 
inhibited by the retinoblastoma gene product (pRb), which 
represses the E2F transcription factor family and activation 
of its downstream targets [2, 4]. In response to activating 
signals such as growth factors or cell adhesion molecules, 
cyclin D1 is produced, and interacts with CDKs 4 and 6 
to form a complex which phosphorylates pRb and lifts the 
repression on E2F, allowing it to activate downstream tar-
gets, and permitting quiescent cells to irreversibly enter the 
DNA synthesis (S) phase of the cell cycle [2–4]. There are 
several indings that have implicated the CDK 4/6 path-
way in breast cancers; these include overexpression and/
or ampliication of D-type cyclins (e.g. CCND1) and CDK 
4 [2, 3]. Preclinical work in breast cancer cell lines from 
Finn and coworkers also showed that estrogen receptor-
positive (ER+) cell lines were most sensitive to CDK 4/6 
inhibition, and evidence for an apparent synergism between 
CDK 4/6 inhibitors and endocrine therapy (tamoxifen) [2]. 
Collectively, these indings have led to the development of 
CDK 4/6 inhibitors as potential therapeutic agents in breast 
cancer. Whereas irst-generation CDK 4/6 inhibitors lacked 
suicient speciicity, resulting in disappointing clinical ei-
cacy and unacceptable toxicities, second-generation agents 
are now available that have shown eicacy in breast cancer 
in both the preclinical and clinical settings; these agents 
include palbociclib, ribociclib, and abemaciclib [5–14].
CDK 4/6 inhibitors: brief summary of clinical 
evidence in mBC
The seminal clinical data supporting the use of CDK 4/6 
inhibitors in combination with endocrine therapy for mBC 
are summarized in Table 1, and includes the PALOMA-1, 
-2, and 3, MONALEESA-2 and -7, and MONARCH-1, -2, 
and -3 studies for palbociclib, ribociclib, and abemaciclib, 
respectively. Of note, whereas both palbociclib and riboci-
clib were approved for use in mBC at the time of the round-
table discussion, abemaciclib had not yet been approved. 
Since that time, results from MONARCH-3 have been sub-
sequently been reported, and abemaciclib was approved 
for use in the mBC setting by the United States Food and 
Drug Administration (US FDA) based on the MONARCH-1 
and 2 trials [15]. As outlined in Table 1, all of these agents 
have been shown to signiicantly and robustly improve the 
endpoint of progression-free survival (PFS) in women with 
HR+ mBC when used in combination with selected endo-
crine therapies. Signiicant improvement in overall response 
rate (ORR) and clinical beneit rate (CBR) with the combi-
nation therapy (compared to endocrine therapy alone) has 
also been observed across these studies (Table 1). There 
are important diferences in terms of toxicities with the 
three agents, which, however, may, at least in part, relate to 
their diferential speciicity for the CDKs [3]. Importantly, 
an overall survival (OS) advantage has not yet been docu-
mented in the setting of mBC (Table 1); thus, the choice of 
which therapeutic line in which to initiate a CDK 4/6 inhibi-
tor is not mandated.
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Table 1  CDK 4/6 inhibitors: summary of key clinical data [5–14]
Agent Trial Study Type and Treatments Population Studied Key Eicacy Findings Key Safety Findings
Palbociclib PALOMA 1 Phase 2; Open-label
Palbociclib or Placebo + Letrozole
Postmenopausal; HR+, HER2−, ABC
~43% of pts had prior CT
Median PFS 10.2 mo for pla-
cebo + letrozole vs. 20.2 mo for 
palbociclib + letrozole (HR 0.488, 
95% CI 0.319–0.748; P = 0.0004).
ORR (43% vs. 33%; P = 0.047) and 
CBR (81% vs. 58%; P = 0.0009) 
favored palbociclib + letrozole
Gr 3/4 Events (palbociclib vs. placebo)
 Neutropenia 54% versus 1%
 Leucopenia 19% versus 0%
 Fatigue 4% versus 1%
 No febrile neutropenia or neutropenia-
related infections
PALOMA 2 Double-blind, Phase 3
Palbociclib or Placebo + Letrozole
Postmenopausal; HR+, HER2− ABC
No prior therapy for advanced disease
Primary eicacy endpoint, PFS, met; 
favors palbociclib (24.8 mo vs. 14.5 
mo; HR 0.58; 95% CI 0.46; 0.72; 
P < 0.001)
Consistent beneit in PFS across 
subgroups
OS data immature at time of analysis
ORR 42.1% versus 34.7%; P = 0.06
CBR 84.9% versus 70.3%; P < 0.001
Most common toxicities (30% or more 
patients) included neutropenia, leu-
copenia, fatigue, nausea, arthralgia, 
alopecia
Febrile neutropenia occurred in 1.8% 
of palbociclib treated patients versus 
0% in placebo group
PALOMA 3 Randomized; Double-blind, Phase 3
Palbociclib or Placebo + Fulvestrant
~ 1/3 with prior CT for metastatic 
disease
HR+, HER2− ABC
Progression on prior endocrine 
therapy
Primary eicacy endpoint, PFS, met 
at interim analysis; favors palboci-
clib (9.2 mo vs. 3.8 mo; HR 0.42; 
95% CI 0.32; 0.56; P < 0.001)
Beneit observed across major sub-
groups examined based on HRs.
OS data immature at time of analysis
ORR 10.4% versus 6.3%; P = 0.16
CBR 34.0% versus 19.0%; P < 0.001
Toxicities occurring in 30% or more 
patients (Palbociclib vs. Placebo); Gr 
3/4, Palbociclib versus Placebo
 Neutropenia (78.8% vs. 3.5%); 62.0% 
versus 0.6%
 Leukopenia (45.5% vs. 4.1%); 25.2% 
versus 0.6%
 Fatigue (38.0% vs. 26.7%); 2.0% 
versus 1.2%
 Low rate of febrile neutropenia (0.6%, 
both groups)
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Table 1  (continued)
Agent Trial Study Type and Treatments Population Studied Key Eicacy Findings Key Safety Findings
Ribociclib MONALEESA-2 Randomized; Double-blind, Phase 3 Postmenopausal; HR+, HER2− 
recurrent or metastatic BC
No prior therapy for advanced disease
Primary eicacy endpoint, PFS, met 
at interim analysis; favors ribo-
cilclib (Not reached vs. 14.7mo; 
HR 0.56; 95% CI 0.43; 0.72; 
P < 3.29 × 10−6)
OS data immature at time of analysis
ORR 40.7% versus 27.5%; P < 0.001
CBR 79.6% versus 72.8%
P = 0.02
Ribociclib also favored in subgroup 
of patients with HR+, HER2− 
ABC at diagnosis (Median PFS not 
reached w/ribociclib vs. 16.4 mo w/
placebo HR 0.45, 95%
CI 0.27–0.75)
Toxicities occurring in 30% or more 
patients (Ribociclib vs. Placebo); Gr 
3/4, Ribociclib versus Placebo
 Neutropenia (74.3% vs. 5.2%); 59.3% 
versus 0.9%
 Nausea (51.5% vs. 28.5%); 2.4% 
versus 0.6%
 Infections (50.3% vs. 42.4%); 4.2% 
versus 2.4%
 Fatigue (36.5% vs. 30.0%); 2.4% 
versus 0.9%
 Diarrhea (35.0% vs. 22.1%); 1.2% 
versus 0.9%
 Alopecia (33.2% vs. 15.5%); Gr 3/4 
not applicable
 Leukopenia (32.9% vs. 3.9%); 21.0% 
versus 0.6%
 Febrile neutropenia occurred within 
4 weeks in 1.5% of patients in riboci-
clib group vs. 0% placebo group
QTc prolomgation occured in 11(3.3%) 
and 1 sudden death in the setting of 
hypokalemia and G2 QTc prolonga-
tion in the ribociclib group
MONALEESA-7 Double-blind, randomized, Phase III
Ribociclib or placebo + tamoxifen/
NSAI and goserelin
Pre- or peri-menopausal women 
with HR+, HER2− ABC who had 
received ≤ 1 line of CT and no prior 
ET for ABC
PFS signiicantly improved with 
ribociclib (median PFS, 23.8 
vs. 13.0 months; HR 0.553; 
P = 9.83 × 10−8)
ORR 51% versus 36% (ribociclib vs 
placebo) arm; P = 3.17 × 10−4)
CBR 80% versus 67%; 
P = 3.40 × 10−4.
Most frequent all-grade AEs; ≥ 25% of 
patients; ribociclib vs placebo arm)
 Neutropenia (76% vs 8%)
 Hot lush (34% vs 34%)
 Nausea (32% vs 20%)
 Leukopenia (31% vs 6%)
 Arthralgia (30% vs 27%)
Gr 3/4 Events in ≥ 5% of patients:
 Neutropenia (61% vs 4%)
 Leukopenia (14% vs 1%)
Febrile neutropenia: 2% versus < 1%
AEs leading to permanent discontinua-
tion: 4% versus 3%
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Table 1  (continued)
Agent Trial Study Type and Treatments Population Studied Key Eicacy Findings Key Safety Findings
Abemaciclib MONARCH-1 Phase 2 single arm
Abemaciclib until PD
HR+/HER2− mBC, PD after ET and 
CT
1–2 lines CT for metastatic disease
Conirmed ORR 19.7%
CBR 42.4%
Median PFS 6.0 mo
Median OS 17.7 mo
Diarrhea, fatigue, and nausea most 
common AEs
7.6% discontinued due to AEs
MONARCH-2 Phase 3; randomized, double-blind 
placebo-controlled
Abemaciclib or Placebo + Fulvestrant
HR+, HER2− ABC PD after ET
No prior CT for ABC
PFS 16.4 mo versus. 9.3 mo (HR 
0.553; 95% CI 0.449; 0.681; 
P < 0.001)
Beneit consistent across subgroups
ORR 35.2% versus 16.1%
P < 0.001
CBR 72.2% versus 56.1%
P < 0.001
Toxicities occurring in 30% or more 
patients (Abemaciclib vs. Placebo); 
Gr 3/4, Abemaciclib vs. Placebo
 Diarrhea (86.4% vs. 24.7%); 13.4% 
versus 0.4%
 Neutropenia (46.0% vs. 4.0%); 26.5% 
versus 1.7%
 Nausea (45.1% vs. 22.9%); 2.7% 
versus 0.9%
 Fatigue (39.9% vs. 26.9%); 2.7% 
versus 0.4%
 Abdominal Pain (35.4% vs. 15.7%); 
2.5% versus 0.9%
MONARCH-3 Abemaciclib or Placebo, + NSAI HR+, HER2− ABC
No prior systemic therapy for meta-
static disease
Primary eicacy endpoint, PFS, 
favors abemaciclib (HR 0.543; 95% 
CI 0.409; 0.723; P = 0.000021); 
beneit observed across subgroups
OS data immature at time of analysis
Response Rate
All patients
ORR favors abemaciclib
(48.2% vs. 34.5%; P = 0.002)
CBR trended better w/abemaciclib
(78.0% vs. 71.5%; P = NS)
Patients with measurable disease at 
baseline
ORR favors abemaciclib
(59.2% vs. 43.8%; P = 0.004)
CBR favors abemaciclib
(79.4% vs. 69.2%; P = 0.024)
Toxicities (30% or more patients, 
Abemaciclib vs. Placebo); Gr 3/4, 
Abemaciclib vs. Placebo
 Diarrhea (81.3% vs. 29.8%); 9.5% 
versus 1.2%
 Neutropenia (41.3% vs. 1.9%); 21.1% 
versus 1.2%
 Fatigue (40.1% vs. 31.7%); 1.8% 
versus 0%
 Nausea (38.5% vs. 19.9%); 0.9% 
versus 1.2%
 1 pt with nonserious febrile neutrope-
nia in abemaciclib arm
 Gr 3/4 neutropenia in 21.1%; not asso-
ciated with neutropenic fever
 Diarrhea (Gr 3) occurred early, 
managed with dose reduction and 
antidiarrheal medications
CBR clinical beneit rate, CT chemotherapy, ET endocrine therapy, HER2 human epidermal growth factor receptor 2, HR+ hormone receptor-positive, NS not signiicant, NSAI nonsteroidal aro-
matase inhibitor, ORR objective response rate, OS overall survival, PD progressive disease, PFS progression-free survival
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CDK 4/6 treatment: what are 
the diferentiators?
What are the diferentiators, current or future, 
that drive your decision to treat using the various 
endocrine options available for the treatment 
of metastatic breast cancer?
In terms of PFS reduction (Tables 1), it was agreed by 
the panel that the three CDK 4/6 inhibitors appear to be 
largely similar in eicacy, and, as noted above, none has 
as yet shown a beneit in OS. The initial discussion was 
focused on the diferentiators, current or future, if any, 
which drive the decision to treat using the various endo-
crine options available for the treatment of mBC. The 
group was not entirely uniform with respect to their use 
of CDK 4/6 inhibitors in the irst-line setting for meta-
static disease. The principal drivers identiied from the 
discussion included whether the patient was symptomatic 
or asymptomatic from the metastatic standpoint, whether 
the metastases were primarily visceral or nonvisceral, 
menopausal status, and the disease-free interval. Some 
participants reported (owing to the current lack of OS 
advantage) being more inclined to use endocrine therapy 
alone if a patient was asymptomatic with relatively indo-
lent disease and had been of endocrine therapy for a few 
years, and in those with de novo, bone only metastatic 
disease. There was general agreement on the early use of 
a CDK 4/6 inhibitor in younger patients and in those with 
aggressive, progesterone receptor-negative (PR−) and/or 
symptomatic disease.
Mutation in ESR1, the gene encoding the estrogen 
receptor and a suspected marker of endocrine therapy 
resistance [16–18], was also cited as a potentially mean-
ingful factor to consider, and an active area of research, 
although among the group, it was not routinely tested for 
outside of a clinical study, and was not used as a determi-
nant for CDK 4/6 inhibitor use. The group did, however, 
cite the potential importance of ESR1 mutation results, 
if available, when deciding to use the selective estrogen 
receptor degrader, fulvestrant or an aromatase inhibitor 
(AI) in combination with CDK 4/6 therapy [18]. Indeed, 
results from PALOMA-3 using circulating tumor DNA 
showed ESR1 mutation in 106 of 395 samples tested 
(26.8%), and all of these patients had been previously 
treated with an AI, whereas no ESR1 mutations were 
found in patients who received tamoxifen only. Also of 
importance from this study was that median PFS was sig-
niicantly longer with the combination of palbociclib + ful-
vestrant as compared to placebo + fulvestrant regardless 
of patient’s ESR1 mutational status [19]. It was noted that 
new technologies for ESR1 mutational testing, such as 
evaluation of circulating tumor DNA, continue to be devel-
oped and, although not currently standard practice, may 
be routinely incorporated into testing in the near future.
A few participants in the group reported using CDK 4/6 
inhibitors as irst-line therapy in a majority of patients, citing 
the robust PFS improvements across all the major studies 
and within subgroups, in which the doublet was consistently 
found to be beneicial over the single-agent endocrine ther-
apy. However, the group acknowledged that market research 
from the major CDK 4/6 developers showed a much lower 
uptake of these agents than would have been expected, based 
upon the clinical results; this suggests that clinicians believe 
they know who will beneit from the drug and who will 
not, or this could be a manifestation of other variables (e.g., 
drug cost). In reality, however, there was agreement that, 
based on Forest plots presented in the major clinical trials, 
all subgroups of patients with HR+, HER2− mBC beneit, 
and there is not at present a clinical feature or biomarker for 
use of these agents, nor is there a clinical outlier whom one 
could reliably predict would, or would not beneit from the 
use of a CDK 4/6 inhibitor with endocrine therapy.
With regard to the lack of OS beneit in the face of the 
robust improvements in PFS, it was suggested that none of 
the major trials may be suiciently powered to detect sur-
vival beneit, and as such, pooling/meta-analysis of trial data, 
as well as further follow up, may be needed to adequately 
evaluate this endpoint. Some participants noted the results 
of a Southwest Oncology Group (SWOG) study showing 
improvement in OS with anastrozole and fulvestrant as irst-
line therapy [20]. Others, however, were more dismissive of 
the SWOG trial, citing its unplanned subgroup analyses and 
suggesting the OS beneit was restricted to patients naïve 
to adjuvant tamoxifen. Another important point raised is 
that OS beneit has become more diicult to attribute to the 
irst-line therapy, since many possible treatment options are 
now available to the patient over time; thus determining the 
impact of a irst-line therapy on OS will become progres-
sively more diicult.
Barriers to use of CDK 4/6 inhibitors
What signiicant clinical toxicities, inancial 
barriers, and/or common community practice 
misunderstandings exist regarding the use of CDK 
4/6 inhibitors?
Several barriers to the widespread use of CDK 4/6 inhibi-
tors were identiied by the group. Whereas there was agree-
ment that the addition of CDK 4/6 inhibitors to endocrine 
therapy resulted in overall low additional toxicity over endo-
crine therapy alone, there was concern over events such as 
fatigue and alopecia with all of the agents, and diarrhea with 
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abemaciclib. In the case of palbociclib, the group expressed 
some concerns regarding alopecia; some felt incidence of 
events such as alopecia was similar with ribociclib, although 
globally the experience with ribociclib in the group was 
more limited.
The group discussed results presented by Finn and cow-
orkers at 2017 ASCO showing that concerns regarding pos-
sible increased incidence or severity of future myelotoxic-
ity upon progression on palbociclib were not substantiated, 
and indicating that chemotherapy delivery and efficacy 
post-palbociclib was not compromised [21]. The group 
felt this was an important point, because if patients were 
to develop worsened myelotoxicity later in the course of 
treatment, this would likely compromise the use of subse-
quent chemotherapies over concerns of further myelosup-
pression. The group also felt it important to highlight that, 
despite the frequent occurrence of neutropenia with these 
agents, the rate of febrile neutropenia was low across the 
trials, and the group did not report utilizing growth factor 
or prophylactic antibiotic support with these agents. Patient-
reported outcome (PRO) and quality of life (QoL) data were 
also cited from ASCO 2017, which compared ribociclib and 
placebo (in combination with letrozole) in patients with 
HR+, HER2− advanced breast cancer (MONALEESA-2 
trial). The results of this trial showed (at least in the case of 
ribociclib) that QoL was not adversely afected, and certain 
measures (e.g., pain reduction) trended better with the addi-
tion of the CDK 4/6 inhibitor [22].
There was discussion surrounding monitoring require-
ments, and how these impact the choice of CDK4/6 inhibitor. 
Electrocardiogram (ECG) monitoring with ribociclib, for 
example (Table 2), was cited as a nuisance by several mem-
bers of the group. Regarding the need for complete blood 
cell (CBC) and other monitoring (Table 2), the panel noted 
the importance of keeping apprised of any prescribing infor-
mation updates. Palbociclib, for example, in its most recent 
update, now recommends CBC to be monitored prior to the 
start of therapy and at the beginning of each cycle, as well 
as on day 15 of the irst 2 cycles, and then less frequently 
(every 3 months) [23]. The update may be beneicial for 
patients who are not inclined to return monthly for CBC 
monitoring and for physicians who prefer to follow patients 
at longer intervals.
Delays in institution of therapy due to the need for dose 
reductions were also cited as a signiicant and costly prob-
lem. Drug wastage was raised as an important issue in light 
of rising healthcare costs. Some participants noted that ribo-
ciclib dose reduction was easier, owing to its blister packag-
ing. Frequent and appropriate dose reductions were reported 
as necessary for both hematologic (e.g., neutropenia) and 
nonhematologic toxicities (e.g., fatigue). Lastly, despite the 
importance of “having the conversation with the patient” 
and ofering CDK 4/6 inhibitors upfront (in absence of any 
contraindications), some in the group noted that patients 
may be inclined to refuse the treatment if the drug costs 
are prohibitive. Indeed, it was agreed that co-pays of up to 
20% could present a signiicant inancial hardship for many 
patients, and, given the lack of survival beneit, there was 
some discussion that PFS beneit alone might not justify the 
cost. It was also noted by the group that the use of CDK 4/6 
Table 2  Currently Approved CDK 4/6 Inhibitors [23, 32, 33]
AI aromatase inhibitor, CBC complete blood count, HER2 human epidermal growth factor receptor 2, HR hormone receptor
Agent (trade name) Year approved Indication Most common adverse events and required 
monitoring
Palbociclib  (Ibrance®) 2015 HR+, HER2− Advanced or metastatic breast 
cancer, in combination with:
A. An AI as initial endocrine based therapy in 
postmenopausal women; or
B. Fulvestrant, in women with disease progres-
sion following endocrine therapy.
(Incidence ≥ 10%) Neutropenia, infections, 
leukopenia, fatigue, nausea, stomatitis, anemia, 
alopecia, diarrhea, thrombocytopenia, rash, 
vomiting, decreased appetite, asthenia, pyrexia
Required Monitoring: CBC
Ribociclib  (Kisqali®) 2017 Postmenopausal women with HR+, HER2− 
Advanced or metastatic breast cancer in 
combination with an AI as initial endocrine-
based therapy.
(Incidence > 20%) Neutropenia, nausea, fatigue, 
diarrhea, leukopenia, alopecia, vomiting, consti-
pation, headache, back pain
Required Monitoring: QT interval prolongation, 
Electrocardiograms (ECGs), Electrolytes, Liver 
Function Tests (LFTs), CBC
Abemaciclib (Verzenio™) 2017 In combination with fulvestrant for HR+, 
HER2−, Advanced or metastatic breast cancer 
with disease progression following endocrine 
therapy; or
As monotherapy for HR+, HER2−, Advanced 
or metastatic breast cancer with disease 
progression following endocrine therapy and 
prior chemotherapy in the metastatic setting
(Incidence ≥ 20%) Diarrhea, neutropenia, nausea, 
abdominal pain, infections, fatigue, anemia, 
leukopenia, decreased appetite, vomiting, head-
ache, thrombocytopenia
Required Monitoring: Liver Function Tests 
(LFTs), CBC, Monitor for venous thrombosis 
and pulmonary embolism
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inhibitors may not ultimately be found to be a cost-efec-
tive intervention; despite this, however, it was felt that cost 
alone should not be a deciding factor on whether to use these 
agents [24–26].
Sequencing Therapies for ER+/HER2– MBC
How would you approach patients that have 
progressed on a CDK 4/6 inhibitor?
With respect to the current status of CDK 4/6 inhibitors in 
the sequence of treatment, the question was raised about 
“saving” CDK 4/6 inhibitor use for a later line of therapy. 
The group cited the higher magnitude of PFS beneit asso-
ciated with combination therapy upfront, as opposed to 
using CDK 4/6 inhibitor in combination with fulvestrant at 
a later time. There was agreement that the irst-line therapy 
a patient receives is generally the one they will continue for 
the longest period of time, and that, in accordance with the 
general principles of oncology, the most efective, and the 
least toxic therapies should be used irst. The group then 
discussed the management of patients who progress on 
AI monotherapy after more than 1 year of disease control. 
Possible considerations included considering ESR1 muta-
tional status to determine if a switch to fulvestrant would 
be appropriate. Fulvestrant therapy was also thought to be 
beneicial in this scenario as it assures compliance due to its 
mode of administration. They acknowledged results from 
the To Reverse ENDocrine resistance (TREND) trial, which 
demonstrated that highly selected patients may beneit from 
adding palbociclib to long-term AI therapy after progression 
(with no change in endocrine therapy), with the caveat that 
this was a small study (N = 115) and the approach should not 
be used routinely in the absence of larger conirmatory data 
[27]. This trial also showed activity of single-agent palboci-
clib in this setting (CBR, 60%), and in this regard, it should 
also be noted that all three agents have been shown to have 
at least some activity as a monotherapy, although at present, 
only abemaciclib is approved as a single-agent treatment 
(Table 2) [2–4, 10, 27–29]
The group was generally in agreement on the upfront 
use of an AI with a CDK 4/6 inhibitor, followed by (upon 
progression) fulvestrant or exemestane with a mamma-
lian target-of-rapamycin (mTOR) inhibitor (e.g. everoli-
mus). The incorporation of everolimus was felt to be 
associated with additional toxicity, albeit manageable 
toxicity with the incorporation of additional measures 
(e.g., steroid-based mouthwash). The data supporting the 
combination of fulvestrant and everolimus were cited as 
the PrECOG 0102 data presented at San Antonio Breast 
Cancer Symposium (SABCS) 2016 [30]. Notably, patients 
in this study had not been treated with prior CDK 4/6 
inhibitors, and another important unresolved issue noted 
by the group (and not addressed in PrECOG 0102) was 
whether CDK 4/6 inhibitor therapy should be continued 
upon progression.
There was agreement that data on switching between 
CDK 4/6 inhibitors are not yet available, and while the 
label for abemaciclib does not exclude patients who previ-
ously received a CDK4/6 inhibitor, the Monarch-1 study 
did not allow prior CDK4/6 inhibitors. Eicacy data for 
abemaciclib monotherapy following progression on a CDK 
4/6 inhibitor are therefore not yet available. The potential 
use of CDK 4/6 inhibitors in combination with tamoxifen 
in pre- and perimenopausal women was also discussed, 
and in this regard, the panel now recognizes recently 
reported results from MONALEESA-7 (SABCS 2017) 
which conirm a beneit of using ribociclib in combina-
tion with tamoxifen (and goserelin) in this patient popula-
tion (Table 1) [14]. At present, there are no data on using 
tamoxifen (without ovarian suppression) and a CDK 4/6 
inhibitor.
Biomarkers for CDK 4/6 inhibitors
What biomarkers, if any, have been shown 
to predict beneit, or lack thereof, when using 
CDK4/6 inhibitors (e.g., ESR1, CND1 ampliication, 
p16 loss, or RB1 expression)?
Regarding the use of biomarkers to predict responses in 
patients treated with CDK 4/6 inhibitors, the panel noted 
the results from PALOMA-1, in which markers such as 
cyclin D1 ampliication and p16 loss did not reliably pre-
dict response to palbociclib [5, 31]. They agreed clini-
cians should not use biomarkers to make treatment deci-
sions, and the only proven biomarker of response per se 
is the estrogen receptor itself. The group also recognized 
the need for phosphorylated pRb in order for the CDK 
4/6 inhibitors to work, and some of the group said they 
would be reluctant to start on a CDK 4/6 inhibitor, if it 
was known the tumor had loss of pRb. This is perhaps 
most relevant for a patient that had progressed on single-
agent AI and for whom such information could be poten-
tially available, whereas for most patients this would not 
be known in the up front setting. The group thought that 
markers of response early in the course of single-agent 
therapy are urgently needed, and cited eforts underway 
to ind markers such as mutational load in serum during 
therapy. At present, however, it was agreed that such mark-
ers are not available.
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Summary and key points
Overall, the group viewed the addition of CDK 4/6 inhibitors 
as a valuable therapeutic option available to women with 
HR+, HER2−, mBC, with the caveat that additional research 
is needed to gain clariication on several important issues 
such as treatment biomarkers, optimal duration of therapy, 
continuation of CDK4/6 inhibitors, and/or a switch to a dif-
ferent drug in the same class following disease progression. 
In light of this BCTEG roundtable discussion, the following 
expert opinion statements can be made:
• Level 1 evidence now supports use of a CDK 4/6 inhibi-
tor in combination with endocrine therapy for patients 
with HR+, HER2−, mBC as irst-line treatment.
• Currently, there are no biomarkers that reliably deine 
patients who will or will not beneit from the addition of 
a CDK 4/6 inhibitor to endocrine therapy; ESR1 muta-
tional status should not restrict use of a CDK 4/6 inhibi-
tor.
• Financial considerations may limit the use of these 
agents, and treatment-related toxicities such as diarrhea 
and fatigue may be dose limiting; although neutropenia 
is a frequent occurrence with these agents, the rate of 
febrile neutropenia is low.
• Additional research is needed to identify the optimal 
sequencing of CDK 4/6 inhibitors in relation to other 
therapies as well as optimal duration of therapy; at pre-
sent, use in the upfront setting is better than waiting for 
a later line of therapy or adding after endocrine therapy 
has started.
Finally, the group agreed that CDK 4/6 inhibitors are an 
important new class of drugs in the management of patients 
with inoperable breast cancer. In addition, it was recognized 
that at present, breast cancer is leading the ield in clinical 
experience with CDK 4/6 inhibitors, and research currently 
underway in breast cancer (e.g., optimal duration of therapy, 
use in combination with other treatments) will be of value to 
many other cancer types such as lung cancer, glioblastoma, 
and melanoma. It was noted, for example, that, although 
their use in combination with endocrine therapy is now well 
established, due to their antiproliferative activity, CDK 4/6 
inhibitors might not be optimally combined with other emer-
gent therapies, such as immunotherapy (which requires T 
cell proliferation), and might in fact act antagonistically with 
some types of chemotherapy. These and other combinations 
await further evaluation in clinical trials.
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